Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 8,506 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasm Recurrent Clear all
Completed Phase 2 Interventional Results available

Cetuximab and Lenalidomide in Head and Neck

NCT01133665
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Cetuximab and Lenalidomide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Nov 6, 2026, 2:05 PM EST
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT03181867
View directory record Official record
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 1 Interventional

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831
View directory record Official record
Conditions
Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia
Interventions
PRT543
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Gilbert, Arizona • San Francisco, California • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00025467
View directory record Official record
Conditions
Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma
Interventions
thalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Nov 6, 2026, 2:05 PM EST
Recruiting Phase 1 Interventional

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

NCT05945875
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 6, 2026, 2:05 PM EST
Terminated Phase 2Phase 3 Interventional Results available

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

NCT02186301
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Burbank, California • Duarte, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00016328
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
temsirolimus, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

NCT00003871
View directory record Official record
Conditions
Prostate Cancer
Interventions
fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Indianapolis, Indiana • Boston, Massachusetts • New Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 6, 2026, 2:05 PM EST
Active, not recruiting Phase 2 Interventional Results available

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

NCT01463072
View directory record Official record
Conditions
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
Duarte, California • Lancaster, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 3 Interventional

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00004001
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine, mitoxantrone, prednisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 1 Interventional

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

NCT00459212
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
GTI-2040, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional

Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer

NCT00004081
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
docetaxel
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

NCT00526292
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
natural killer cell therapy, cyclophosphamide, fludarabine
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 3 Interventional

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

NCT04338399
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Buparlisib & Paclitaxel
Drug
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
21
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

NCT02907099
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 1 Interventional

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00016172
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pegylated liposomal doxorubicin hydrochloride, picoplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

NCT01462695
View directory record Official record
Conditions
Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

NCT00101101
View directory record Official record
Conditions
Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 6, 2026, 2:05 PM EST
Terminated Phase 2 Interventional

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

NCT00498901
View directory record Official record
Conditions
Breast Cancer
Interventions
goserelin, letrozole, leuprolide acetate, conventional surgery
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Nov 6, 2026, 2:05 PM EST
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

NCT00003907
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
cisplatin, doxorubicin, mitomycin, embolization
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
37
States / cities
Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Nov 6, 2026, 2:05 PM EST
Terminated Phase 1 Interventional

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

NCT04327011
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant
Interventions
Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Nov 6, 2026, 2:05 PM EST
Completed Phase 2 Interventional Results available

Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT00553644
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma
Interventions
Bortezomib, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
82
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Nov 6, 2026, 2:05 PM EST